

FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7708

TELEPHONE (858) 552-1311


COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

April 15, 2004

MORGAN L. FITCH, JR.
FRANCIS A. EVEN*
JULIUS TABIN
JOHN F. FLANNERY
ROBERT B. JONES
JAMES J. SCHUMANN
JAMES J. HAMILL
TIMOTHY E. LEVSTIK
JOSEPH E. SHIPLEY
KENNETH H. SAMPLES
PHILIP T. PETTI
JOSEPH T. NABOR
STEVEN C. SCHROER
RICHARD A. KABA*
KARL R. FINK
MARK W. HETZLER
TIMOTHY P. MALONEY
JAMES P. KRUEGER
STEPHEN S. FAVAKEH
RICHARD E. WAWRZYNIAK
STEVEN G. PARMELEE
THOMAS F. LEBENS
BRUCE R. MANSFIELD
KENDREW H. COLTON*
G. PAUL EDGELL*
MICHAEL A. SANZO*
SCOTT A. MENGHINI
NORMAN N. KUNITZ*
RUDY KRATZ
RAMON R. HOCH*



EDWARD E. CLAIR
JON A. BIRMINGHAM
JOHN E. LYHUS
STEVEN M. FREELAND
DONNA E. BECKER
MICHAEL G. VRANICAR
BRIAN S. CLISE
MARTIN R. BADER
DEREK L. PRESTIN
MARK A. BORSOS
DAVID R. JAGLOWSKI
TIMOTHY R. BAUMANN
JEFFREY A. CHELSTROM
NICHOLAS T. PETERS
KENNETH A. PLOCHINSKI
MEGAN J. REDMOND

PATENT AGENTS

ERIC J. WHITESSELL
LILIA I. SAFONOV

OF COUNSEL

GEORGE W. SPELLMIRE, JR.
LISA M. SOMMER
GEORGE H. SPENCER, P.C.*

TECHNICAL ADVISOR

JOHN M. BRONK, Ph.D.

*ADMITTED TO D.C. BAR; D.C. PRACTICE OF
ALL OTHERS LIMITED TO FEDERAL COURTS
AND AGENCIES

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MS Reissue
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

10/811,793

Re: Information Disclosure Statement
(Reissue of U.S. 09/571,751, now U.S. 6,479,551)
Appl. No.: 10/811,793
Filed: March 29, 2004
Title: **Treatment of Migraine Headache**
Inventor(s): Plachetka, *et al.*
Atty. Dkt.: 7569/80993

Dear Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. Information Disclosure Statement;
2. PTO Form-1449, List of References Cited by Applicant;
3. References AA1, AH1-AI1, and AL1-AR1; and
4. Return postcard.

Applicants do not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7569/80993.

Commissioner for Patents
April 15, 2004
Page 2

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in black ink, reading "Michael A. Sanzo". The signature is written in a cursive, flowing style.

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

MAS:ct
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue patent application of:

Plachetka, *et al.*

Appl. No.: 10/811,793

Filed: March 29, 2004

For: **Treatment of Migraine Headache**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7569/80993

Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **MS Reissue**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents are also enclosed.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned attorney submits the following concise explanation of the relevance of the non-English language document cited on the accompanying form:

Reference AI1, Japanese patent document JP 58-8020, describes an alkaline tablet for making a buffered aspirin formulation. The tablet contains a calcium or magnesium base plus neutralization accelerators. An English language abstract corresponding to this document is cited on the accompanying list of references as document AR1. In addition, an English language Canadian counterpart of this patent, CA 1,165,242, is enclosed and cited on the accompanying list of references as document AH1. A counterpart U.S. patent, US 4,664,915 is also enclosed and is cited on the accompanying list of references as document AA1.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7569/80993.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo

By

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

Date April 15, 2004
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				Atty. Docket No.: 7569/80993		Appl No.: 10/811,793	
				Applicant(s) Plachetka, <i>et al.</i>			
				Filing Date: March 29, 2004		Group: to be assigned	

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA 1	4,664,915	May 12, 1987	Simonian	424	128	Feb. 21, 1986
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Abstr./Trans.	
							Yes	No
	AH 1	CA 1,165,242	Apr. 10, 1984	Canada	A61K	31/605		
	AI 1	JP 58-8020	Jan. 18, 1983	Japan	A61K	47/00	X	
	AJ							
	AK							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AL 1	Day, <i>et al.</i> , "Evaluation of an Enteric Coated Aspirin Preparation," <i>Aust. N.Z. J. Med.</i> 6:45-50 (1976).
	AM 1	Internet Advertisement for Migraleve.
	AN 1	Material Safety Data Sheet for Paracetamol D.C. (P.G.S.)
	AO 1	Abstract for <i>Powder Technology</i> 33:107-111 (1982), Krycer, <i>et al.</i> , "The Role of Intra-Granular Porosity in Powder Compaction."
	AP 1	Abstract for <i>Drug. Dev. Ind. Pharm.</i> 26(8):885-889 (2000), Railkar, <i>et al.</i> , "Evaluation and Comparison of a Moist Granulation Technique to Conventional Methods."
	AQ 1	Abstract for <i>Drug. Dev. Ind. Pharm.</i> 27(4):337-343 (2001), Railkar, <i>et al.</i> , "Use of a Moist Granulation Technique (MGT) to Develop Controlled-Release Dosage Forms of Acetaminophen."
	AR 1	Abstract for JP 58-8020, reference AI1 above.
	AS	

Examiner	Date Considered
----------	-----------------